The Disrupt 50

An index of the top private innovators shaping the future of tech and pushing the boundaries of human achievement.

SELECT MONTH TO DISPLAY

Innovator Spotlight: OpenEvidence

State of the Market

OpenEvidence is a leading AI-powered clinical decision support platform that delivers instant, evidence-based answers to verified physicians at the point of care. Drawing from authoritative sources and medical journals, the platform synthesizes vast medical literature into clear, actionable insights via a secure, HIPAA-compliant chatbot and mobile apps.

In an industry overwhelmed by rapidly doubling medical knowledge and persistent physician shortages, OpenEvidence disrupts traditional static references by deploying agentic AI agents capable of autonomous, cross-referenced research. Recent momentum underscores its traction: the company hit one million clinical consultations in a single day in March 2026 and expanded EHR integrations such as Mount Sinai’s Epic system. While legacy competitors like UpToDate and Elsevier’s ClinicalKey AI provide established but less dynamic resources, OpenEvidence’s rapid adoption signals a broader industry pivot toward embedded, generative AI tools. The tools promise to boost accuracy, reduce cognitive load, and drive workflow efficiency.

Looking forward, OpenEvidence envisions “medical super-intelligence” through multimodal, specialist AI agents that not only answer queries but uncover novel connections across literature, ultimately freeing clinicians for higher-value patient care. As healthcare accelerates integration of AI directly into clinical workflows, the company is well-positioned to lead this transformation against intensifying competition.

Deal Metrics

Median

Recent Deal Size

$1.0 B

19.2% monthover month

Median

Raised to Date

$1.6 B

0.8% monthover month

Median

Time Between Financing Rounds

0.7 years

12.2% monthover month

Average

Recent Deal Size

$10.8 B

16.8% monthover month

Average

Raised to Date

$9.8 B

20.1% monthover month

Average

Time Between Financing Rounds

1.0 years

0.2% monthover month


Top Disrupt 50 Investors

1

Andreessen Horowitz

Menlo Park, CA

13companies
2

Sequoia Capital

Menlo Park, CA

13companies
3

Nvidia (NAS: NVDA)

Santa Clara, CA

11companies
4

Coatue Management

New York, NY

10companies
5

DST Global

George Town, Cayman Islands

7companies
6

General Catalyst

San Francisco, CA

7companies
7

Lightspeed Venture Partners

Menlo Park, CA

7companies
8

Octant Ventures

San Francisco, CA

7companies
9

Thrive Capital

New York, NY

7companies

The Disrupt 50

Tap any company for additional details.

RankRank MoveCompanyPost MoneyExpand row
1SpaceX$1,250.0B
2Anthropic$965.0B
3OpenAI$852.0B
4Stripe$159.0B
5Databricks$134.0B
6Waymo$126.0B
7Revolut$100.0B
8Anduril Industries$61.0B
9Cursor$52.0B
10Ripple$40.0B
11Figure AI$39.0B
12Project Prometheus$38.0B
13Ramp$32.0B
14Safe Superintelligence$32.0B
15VAST Data$30.0B
16Motional$28.2B
17Reflection AI$27.5B
18Cognition$26.0B
19Epic Games$22.5B
20Kalshi$22.0B
21Perplexity AI$20.0B
22Kraken$20.0B
23Helsing$18.0B
24Deel$17.3B
25Rippling$16.8B
26Sierra$15.8B
27Veeam$15.0B
28Applied Intuition$15.0B
29Surge AI$15.0B
30Nscale$14.6B
31Skild AI$14.0B
32Shield AI$12.7B
33Labs Companies$12.5B
34Clear Street$12.0B
35Airwallex$12.0B
36OpenEvidence$12.0B
37Whatnot$11.5B
38Notion$11.0B
39Harvey$11.0B
40ElevenLabs$11.0B
41Quantinuum$10.8B
42Colossal Biosciences$10.3B
43WHOOP$10.1B
44Crusoe$10.0B
45Thinking Machines Lab$10.0B
46Mercor$10.0B
47Neuralink$9.7B
48Polymarket$9.6B
49Grafana Labs$9.5B
50Vercel$9.3B

Data that informs the Disrupt 50 index is collected as of the last day of the previous month.

Metric definitions:

  • Rank: Based on the most recently available post money value estimate.
  • Move: The rank move from the previous month.
  • Post Money: The most recently disclosed or estimated post money value based upon available information.
  • Recent Deal: The most recent deal either publicly disclosed or announced.
  • Value Trend: The trend in post money value. A down arrow suggests that the most recent round was a down round.

The information contained in this newsletter is for general information purposes only. The information is provided by Scalar and while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the newsletter or the information, products, services, or related graphics contained in the newsletter for any purpose. Any reliance you place on such information is therefore strictly at your own risk.

In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this newsletter. However, Scalar takes no responsibility for, and will not be liable for, the newsletter being temporarily unavailable due to technical issues beyond our control.

Every effort is made to keep the newsletter up and running smoothly. However, Scalar takes no responsibility for, and will not be liable for, the newsletter being temporarily unavailable due to technical issues beyond our control.

Data Sources: S&P Global Market Intelligence and PitchBook Data, Inc. Data was also retrieved from various sources using Google's Gemini.

Get the monthly The Disrupt 50 delivered to your email

** By clicking the button I agree to receive a monthly E-mail from Scalar